Inflammation of the intestine causes pain and altered motility, at least in part through effects on the enteric nervous system. While these changes may be reversed with healing, permanent damage may contribute to inflammatory bowel disease (IBD) and post-enteritis irritable bowel syndrome. Since little information exists, we induced colitis in male Sprague-Dawley rats with dinitrobenzene sulfonic acid and used immunocytochemistry to examine the number and distribution of enteric neurons at times up to 35 days later. Inflammation caused significant neuronal loss in the inflamed region by 24 hours, with only 49% of neurons remaining by days 4 to 6 and thereafter, when inflammation had subsided. Eosinophils were found within the myenteric plexus at only the earliest time points, despite a general infiltration of neutrophils into the muscle wall. While the number of myenteric ganglia remained constant, there was significant decrease in the number of ganglia in the submucosal plexus. Despite reduced neuronal number and hyperplasia of smooth muscle, the density of axons among the smooth muscle cells remained unchanged during and after inflammation. Intracolonic application of the topical steroid budesonide caused a dose-dependent prevention of neuronal loss, suggesting that evaluation of anti-inflammatory therapy in inflammatory bowel disease should include quantitative assessment of neural components. (Am J Pathol 1999, 155:1051–1057)

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammation of the intestine that affects an increasing percentage of the population in Western society, with the highest incidence among the younger population, for whom there are no specific or effective treatments. The broad acting anti-inflammatory agents in wide use have serious side effects of immune suppression, loss of bone calcium, and growth retardation. Therefore, a strong need exists for increased information about the cellular basis of this disease, as well as new pharmacological tools and improved methods of use.

Studies of IBD have relied heavily on immunological approaches, relating activation of immune cells to the periodic exacerbation and remissions of disease. However, a particular challenge lies in understanding the long-term or permanent changes present in the intestine in IBD, which are evident even in the periods of remission between acute episodes. Recently, attention has been paid to the other cell types in the intestine that may acquire the ability to participate in inflammation or that are previously unexpected targets of inflammatory change. This has shown that nonimmune cells can participate directly in inflammation, as well as pointing out the potential for long-term alterations in cell structure and function that may predispose to repeated episodes of inflammation. Thus, intestinal smooth muscle has been shown to have the potential to present antigen to activated T cells and may also be a source of cytokines that can directly affect neural function.
alter release of neurotransmitters and may thus affect the ENS acutely. However, longer term challenges to neural function may come from either an adaptive response to an altered cellular environment, such as a requirement for innervation for newly arisen target cells in the mucosa or smooth muscle layers or from irreversible damage to the non-renewing population of neurons. Earlier, we had shown that intestinal inflammation causes extensive smooth muscle growth in rat models of jejunitis and colitis, a process that contributes to the thickened intestinal wall seen in IBD and can ultimately lead to intestinal stricturing in Crohn’s disease. This is evidence of both an increase in cells which are normally innervated, as well as further evidence that inflammation can affect cells throughout the intestinal wall. Therefore, we used a model of chemically induced colitis in the rat to study the effects of inflammation on neuronal number in the ENS, as well as axonal density within the smooth muscle. In addition, we have explored the potential for beneficial effects of topical application of the novel steroid budesonide of preserving intestinal innervation.

**Materials and Methods**

**Animals**

Male Sprague-Dawley rats (180–200 g) were obtained from Charles River Laboratories (Quebec, Canada) and were housed in pairs in microfilter isolated cages with free access to food and water. All experimental procedures were approved by the local Animal Research Ethics Board, in accordance with the guidelines of the Canadian Council on Animal Care.

All rats were housed for at least 7 days before experimental use, and food was removed for 24 hours before induction of colitis by intrarectal instillation of dinitrobenzene sulfonic acid (DNBS; ICN). For this, 29 mg of DNBS was dissolved in 250 μl of 50% ethanol and instilled into the colon 8 cm proximal to the anus with a PE50 catheter while the rat was under light anesthesia. Control and vehicle control groups received either 0.9% saline or 50% ethanol alone. Some animals received the anti-inflammatory steroid budesonide (Sigma) in 10% ethanol at doses from 300 to 1000 μg/kg body weight, delivered by rectum.
as a 1-ml solution, as described by Jacobson et al.7 Budesonide was given at 24 hours and 2 hours before the installation of DNBS or the control solutions and at daily intervals thereafter.

Histology

Animals were sacrificed by cervical dislocation under halothane anesthesia at various times after initiation of colitis. The descending colon was rapidly removed after noting the location of the inflamed region and fixed in 10% neutral buffered formalin for 24 hours before routine processing for paraffin sectioning. For longitudinal sections, the colon was cut open along the midline following fixation and embedded so that subsequent sectioning produced parallel sections through the mid-region. For cross-sections, 0.5-cm segments of colon were removed beginning distal to the middle of the inflamed region. For comparison, 0.5-cm segments of noninflamed colon were taken beginning 0.5 cm proximal to the margin of the inflamed region.

Histological sections (4 μm) were stained with hematoxylin and eosin for routine examination or with Congo red for detection of eosinophils. Immunocytochemistry with an antibody to the pan-neuronal marker PGP 9.5 (UltraClone, Isle of Wight, UK) was used to detect neurons and their extensions, with visualization with diamobenzidine and counterstaining with hematoxylin.

Ganglia were identified as discrete aggregations of PGP-positive cells, located either between the smooth muscle layers (myenteric plexus) or between the mucosa and circular smooth muscle layer (submucosal plexus). Within the ganglia, neurons were considered as cells with PGP-positive cytoplasm and a hematoxylin-stained nucleus. The number and distribution of myenteric neurons and ganglia were determined in longitudinal sections by analysis of adjacent microscope fields throughout the length of the inflamed area, defined as showing mucosal damage and inflammatory infiltrate. This represented at least 35 adjacent microscope fields (approximately 7.5 mm) in each of the two parallel intestinal profiles for each tissue. The mean number of neurons per millimeter was calculated for each tissue, and then averaged among tissues.8 This was verified by image analysis (data not shown).

The density of innervation was considered to be proportional to the number of axons (“axon density”) and this was determined by counting the number of PGP-positive axon profiles in 6 nonadjacent microscope fields taken within each of the longitudinal or circular smooth muscle layers, with exclusion of fields containing blood vessels or the myenteric plexus. At the same time, the number of smooth muscle nuclei within the fields was recorded, using nuclear appearance to exclude immune cells. The axon density was calculated and expressed as axons per 10 smooth muscle nuclei.

Myeloperoxidase

Samples of colon (approximately 0.5 cm) were removed from the inflamed region or from areas 1.5 to 2.0 cm proximal to the affected region, cleaned of mesentery and luminal contents, snap-frozen in liquid nitrogen and stored at −70°C until assay. The tissues were weighed, homogenized on ice in buffer, centrifuged for 2 minutes (13,000 × g) and 10-μl aliquots reacted with 100 μl of the peroxidase substrate (TNB peroxidase substrate system; K&P) for 10.0 minutes, when the reaction was stopped with 100 μl of sulfuric acid. The optical density (450 nm) of the reaction product was determined and expressed as ng/ml based on a standard curve using horseradish peroxidase (Sigma).

Statistical Analysis

Results are expressed as the mean ± SE of n observations, where n is the number of animals. Statistical significance was determined by analysis of variance, where P < 0.05 was considered significant.

Results

DNBS Colitis

Rats receiving DNBS developed bloody diarrhea by day 6, while control groups receiving either saline or ethanol solution appeared normal. DNBS-treated rats showed an initial weight loss over the first 2 days, which was then reversed to show an average weight gain by day 6 of 6.7 ± 0.8%9 relative to starting values, while the saline control group increased in weight by 19.0 ± 0.3%9 over the same period. By day 6, the mid-descending colon of DNBS-treated rats showed a prominently inflamed region, with a mean length of 2.7 ± 0.4 cm. Figure 1A shows the typical microscopic appearance of the colon on day 6, with severe mucosal damage, submucosal ulceration, and prominent inflammatory infiltrate. No abnormalities were detected in the histology of tissues from animals receiving saline or ethanol solutions. Examination of cohort rats on day 35 after DNBS treatment showed an overtly normal colon.

Assessment of Neuron Number

PGP immunocytochemistry of the control colon showed prominent neurons within the ganglia of the myenteric and submucosal plexuses, and darkly stained axons within the smooth muscle layers. Examination of the number of neurons in the myenteric plexus of the control colon showed a uniform distribution among regions spanning the area likely to be affected by DNBS: 1.5 cm segments taken at the splenic flexure, the mid-descending region and the distal colon had similar numbers of neurons per millimeter.
neurons at 12.2 ± 0.5, 11.9 ± 1.4, and 11.3 ± 0.9 neurons/mm, respectively.

In DNBS-treated rats at day 6, myenteric plexus neurons in the inflamed region of the colon could still be clearly distinguished with unchanged intensity of staining (Figure 1B). However, the number of myenteric neurons per millimeter was significantly decreased when compared with the equivalent location in control animals, decreasing by nearly 50% to 6.8 ± 0.4 neurons/mm compared with saline control (12.4 ± 0.9 neurons/mm; Figure 1C). The decrease in neuron number was limited to the overtly inflamed region, since examination of 0.5-cm segments taken 0.5 cm from the proximal and distal margins of the inflamed area in day 6 rats showed that the neuron number was similar to control values (data not shown). There was no significant change in the number of myenteric neurons per millimeter in the colons of rats receiving either saline or ethanol control solutions when compared with untreated controls (data not shown).

Examination of the time course of DNBS treatment showed that neuron number per millimeter was significantly decreased by day 2, to 62.0% of control (Figure 1C). Further decrease occurred by day 4, reaching a level of 48.8% of control. All values of myenteric neuron number/mm were similar from day 4 and thereafter, up to day 35 after DNBS, indicating an irreversible loss of myenteric neurons. Examination at very early time points (Figure 1C, inset) showed that a trend to decrease was detectable by even 6 hours after DNBS, with significant decrease by 24 hours.

**Effect of Colitis on Myenteric and Submucosal Ganglia**

Initially, we suspected that the decreased neuron number in DNBS-treated rats could be due to loss of entire ganglia from the myenteric plexus, due to the obvious mucosal damage and transmural inflammation. However, the number of myenteric plexus ganglia per millimeter did not decrease significantly through the time course of colitis (Figure 2A). To estimate the neuronal content of myenteric ganglia, we determined the mean number of neurons per ganglion appearing in the histological sections by counting the number of PGP-positive cells containing a nucleus within each ganglion. This value (“apparent neuronal content”) was consistent among control tissues (3.4 ± 0.4), and was assumed to be representative of ganglionic neuronal content. A comparison among tissues from animals during DNBS-induced inflammation showed a significant decrease in neuronal content by day 1 (P < 0.05), which was then constant thereafter, through day 35 (Figure 2B).

Analysis of neurons within the submucosal plexus, lying much closer to the region of overt damage, showed a significant decrease in neuron number during colitis, from 68.3 ± 4.8 to 41.7 ± 8.7 neurons per cross-section by day 6 of inflammation. This was correlated with a significant drop in the number of ganglia, from 36.6 ± 6.0 to 21.7 ± 3.3 ganglia/cross section by day 6. There was no significant change in the apparent neuronal cell number and a thickened smooth muscle layer.

**Figure 2.** Reduction in neuronal content of myenteric ganglia in DNBS-induced colitis. A: Evaluation of the number of myenteric ganglia per millimeter showed no significant change during the course of inflammation. B: Estimation of the apparent neuronal content of the myenteric ganglia during DNBS colitis. The number of myenteric neurons (PGP-positive cells with nuclei present in the section) was determined in histological sections and showed significant reduction on day 1 after DNBS and thereafter. Bars, means ± SEM of values from 3 to 5 animals per time point. C: Determination of axon density within the longitudinal and circular smooth muscle layers of the colon during DNBS colitis. In areas within the smooth muscle layers, the ratio of PGP-positive axon profiles to the number of smooth muscle nuclei was determined, reflecting innervation by axons originating from both intrinsic and extrinsic sources. This value was not significantly different among day 0 (saline control), day 6, and day 16 tissues, despite decreased neuronal cell number and a thickened smooth muscle layer.
content of the submucosal ganglia (1.94 ± 0.212 versus 2.04 ± 0.511 on day 6). Therefore, we concluded that colitis caused the loss of ganglia from the submucosal plexus, in contrast to the partial loss of neuronal content from the myenteric plexus.

Axon Density in Smooth Muscle

The decrease in neuronal number seen in colitis might lead to decreased innervation of the intestinal smooth muscle, where hyperplasia of the smooth muscle cells is also present and responsible for thickening of the smooth muscle layers. Therefore, we tested whether colitis was associated with a decrease in axon density among the smooth muscle cells, using PGP immunoreactivity to detect axons in the smooth muscle layers, and comparing this with the number of smooth muscle nuclei. The axon density in the smooth muscle layers was unchanged during and after the DNBS-induced inflammation, measured separately in longitudinal and circular smooth muscle layers at days 6, 16, and 35 after DNBS treatment (Figure 2C). This implies that an increase in axon number has occurred rapidly during inflammation.

Involvement of Immune Cells in Neural Damage

Measurement of myeloperoxidase (MPO) activity was used to reflect the presence of neutrophils in the tissue, and this showed the greatest increase in the colon of animals at early time points following DNBS administration. The MPO was significantly increased from the control level of 0.1 ± 0.111 by day 1 (11.5 ± 1.111 ng/ml), and remained elevated through day 6 (2.3 ± 0.411 ng/ml). No significant increase occurred in saline or ethanol-treated
controls, and the MPO was similar to control by day 16 and thereafter. Due to the correlation between the rapid increase in MPO values and the early onset of damage to the myenteric plexus, we examined the histology of tissues at the early time points of 6 and 24 hours after DNBS. We found that eosinophils were characteristically detected within the myenteric plexus ganglia at these times (Figure 3, A and B). While large numbers of neutrophils were already present in the surrounding smooth muscle, they were rarely detected within the ganglia until day 2 (Figure 3B), suggesting that eosinophils may be responsible for neuronal damage and loss.

Due to this evidence suggesting a direct involvement of immune cells with neuronal loss, we investigated whether anti-inflammatory therapy could influence the extent of damage to the enteric nervous system in this model of colitis. Delivered as a daily enema, budesonide caused the dose-dependent prevention of the loss of myenteric plexus neurons in DNBS-treated rats, with a dose of 1000 µg/kg being completely successful in preventing significant loss of myenteric plexus neurons, while lower doses also achieved significant improvement over untreated controls (Figure 3C). Reduction in the MPO levels of DNBS-treated rats occurred in proportion to the dose of budesonide, while carrier alone was without effect (Figure 3D). Budesonide treatment did not affect organ weight of thymus, spleen, or adrenals at any dose (n = 3 per dose; data not shown).

**Discussion**

The autonomous function of the intestine largely depends on appropriate regulation by the ENS. We have used an animal model to show that the ENS undergoes major structural damage during inflammation and we present evidence suggestive of compensating axonal proliferation. This suggests that the loss of neurons within the ENS is an important consequence of intestinal inflammation and may be a significant cause of dysfunction seen in post-enteritis IBS in humans.

In our study of DNBS colitis, we found severe transmural inflammation from day 2 onward, which appeared to be resolved by day 35, with only a thickened muscle wall as a consequence. However, examination showed a significant and lasting decrease in neuron number, by nearly 50% on day 6 that remained through day 35. While an extensive inflammatory infiltrate developed in the muscle wall, and was correlated with significant increases in MPO levels, immune cells were observed within the myenteric ganglia only at the earliest time points of ≤24 hours after DNBS. This suggests that the early events that occur during the inflammatory episode are responsible for the loss of both submucosal and myenteric plexus neurons.

The observed decrease in the number of neurons was not due to transient loss of expression of the marker protein, since PGP-positive neurons remained detectable in inflamed tissue with an unaltered intensity of staining, and the number remained low after inflammation was resolved. Since the apparent number of neurons in each myenteric ganglion decreased during colitis and remained unchanged after healing, while the number of ganglia remained largely unchanged, it appears that inflammation caused loss of a proportion of the neurons within each ganglion. In contrast, a decrease in the number of submucosal neurons was associated with a significant decrease in the number of submucosal ganglia. This may occur due to the potentially greater severity of inflammatory damage closer to the mucosal surface.

It is not yet clear whether cell death occurs proportionally among all neural phenotypes in the inflamed intestine, which could have the additional consequences of altered control of diverse intestinal functions including contractility and mucosal transport. However, the effects of loss of enteric neurons will be superimposed on alterations in neural function that are already present in the inflamed intestine. This is most clearly seen in animal models, where altered neurotransmitter release occurs, and long-lasting up-regulation in acetylcholine synthesis can be detected.

Further studies are required to identify the mechanism of death of enteric neurons. It is possible that increased production of nitric oxide during inflammation is involved, since NO production has been implicated in neuronal injury following ischemia, trauma, and in several neurodegenerative diseases. Elsewhere, inhibition of nitric oxide synthase was found to prevent apoptotic death of neurons in vivo. Earlier, we found that oral delivery of a NO synthase inhibitor prevented the appearance of damage to enteric neurons in colitis, thus supporting a role for this molecule in neuronal cell death.

This study suggests that neuronal plasticity is an important homeostatic mechanism in the intestine, both during and following inflammation. Challenges to the normal patterns of innervation in this model include loss of neurons, an increase in smooth muscle cell number, and an unknown degree of damage to surviving axons. Nonetheless, the density of axons among the smooth muscle cells was maintained during and after inflammation, suggesting rapid axonal proliferation occurs in the inflamed colon. Since the methods used did not discriminate among axons of extrinsic versus intrinsic origins, it is possible that axonal proliferation by both populations is involved in the maintenance of innervation density.

In a recent study, the distribution of axons containing substance P and VIP showed extensive changes during TNBS-induced colitis, with an initial decrease followed by increased expression and a return on day 7 after TNBS to control values. This suggests that intrinsic neurons may undergo axonal proliferation to maintain the innervation of the smooth muscle cells. In the mucosa, neural plasticity may be an essential part of repair, as suggested by the early degeneration and later regeneration of mucosal axons in the jejunum of the rat during *Nippostrongylus*–induced inflammation.

The mechanisms that lead to axonal proliferation in the intestine are not known. Intestinal smooth muscle cells may produce neurotrophic factors that regulate their own innervation, which could be critical during inflammation-induced remodelling of the intestine. For example, nerve growth factor (NGF) and its receptor trkA are expressed on vascular smooth muscle in vivo and in vitro, where
promotion of NGF expression by platelet-derived growth factor, transforming growth factor-β and IL-1β supports the likelihood of its production in the inflamed intestine. Also, NT-3 is implicated due its ability to cause neuronal crest cells from fetal gut to differentiate into neurons and glia.10

The effects of inflammation on intestinal innervation in IBD are less clear, where there is controversy as to the extent, nature, and diagnostic value of such alterations.12 There are no definitive studies of neuron number in IBD, although older reports suggest that there could be either an increase20 or a decrease in a limited study.21 It seems clear that there is axonal necrosis2,22,23 as well as axonal hyperplasia.24,25 Alterations in neurotransmitter levels occur, although conflicting findings may arise from local variation in tissue characteristics as well as variable progression and disease among patients.26

To mimic one form of clinical therapy relevant to treatment of colitis, we used the novel anti-inflammatory steroid budesonide delivered as a daily enema and investigated its ability to control the loss of enteric neurons described above. While the lower doses of budesonide achieved a significant reduction in neuronal loss, the highest dose administered completely prevented this decrease. Similarly, Palmen et al27 recently described that intracolonic budesonide was more effective than dexamethasone in reducing macroscopic damage score in TNBS colitis. Previously, Jacobson et al28 showed that inflammation caused a decrease in K+-evoked release of 3H-noradrenaline from extrinsic nerves of the rat colon, and that this could be attenuated by treatment with budesonide or an IL-1 receptor antagonist.

In these studies, budesonide was effective at doses that did not cause alterations in organ weights of thymus, spleen, or adrenals. These findings reflect the reduced systemic effects of this drug relative to other steroids due to the nearly complete first-pass metabolism after topical action, making it desirable as a therapeutic agent.28

Taken in conjunction with the present study, this shows that anti-inflammatory therapy can both prevent permanent damage as well as ameliorate transient changes in functional properties of intestinal innervation. This may explain the part of the beneficial actions of budesonide and similar compounds in the therapy of IBD.29 Overall, there is a strong need to evaluate neuronal damage in IBD and to determine the best way for current therapies to minimize permanent damage.

References